Bristol Myers (BMY) Squibb announced that the U.S. FDA has accepted a New Drug Application for iberdomide combined with standard treatment in patients with relapsed or refractory multiple myeloma. Iberdomide is part of an investigational, new class of medicines called cereblon E3 ligase modulator agents. The FDA has granted a Prescription Drug User Fee Act date of August 17, 2026 for this indication.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers’ treatment of follicular lymphoma granted FDA orphan designation
- BMY-Backed Milvexian Stroke Trial Moves Forward, Keeping Upside Optionality Alive
- Bristol-Myers Squibb Expands Real-World MDS Footprint in Asia With New Registry Study
- Bristol-Myers Squibb: Solid Near-Term Execution and 2026 EPS Boost from Eliquis, but Limited Long-Term Visibility Supports Hold Rating
- Bristol Myers price target raised to $40 from $37 at Morgan Stanley